<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35568729</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>TDP-43 regulates cholesterol biosynthesis by inhibiting sterol regulatory element-binding protein 2.</ArticleTitle><Pagination><StartPage>7988</StartPage><MedlinePgn>7988</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7988</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-12133-4</ELocationID><Abstract><AbstractText>Dyslipidemia is considered an essential component of the pathological process of amyotrophic lateral sclerosis (ALS), a fatal motor neuron disease. Although TAR DNA Binding Protein 43&#xa0;kDa (TDP-43) links both familial and sporadic forms of ALS and cytoplasmic aggregates are a hallmark of most cases of ALS, the molecular mechanism and the in vivo relation of ALS dyslipidemia with TDP-43 have been unclear. To analyze the dyslipidemia-related gene expression by TDP-43, we performed expression microarray and RNA deep sequencing (RNA-Seq) using cell lines expressing high levels of TDP-43 and identified 434 significantly altered genes including sterol regulatory element-binding protein 2 (SREBP2), a master regulator of cholesterol homeostasis and its downstream genes. Elevated TDP-43 impaired SREBP2 transcriptional activity, leading to inhibition of cholesterol biosynthesis. The amount of cholesterol was significantly decreased in the spinal cords of TDP-43-overexpressed ALS model mice and in the cerebrospinal fluids of ALS patients. These results suggested that TDP-43 could play an essential role in cholesterol biosynthesis in relation to ALS dyslipidemia.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Egawa</LastName><ForeName>Naohiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iPSC-Based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, The University of Tokushima Graduate School, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Hidefumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iPSC-Based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuge</LastName><ForeName>Itaru</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, The University of Tokushima Graduate School, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimano</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumikawa</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Nobuhiro</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Applied Biological Science, Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukita</LastName><ForeName>Kayoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iPSC-Based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enami</LastName><ForeName>Takako</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical-Risk Avoidance Based On iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naitoh</LastName><ForeName>Motoko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Shigehiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seki</LastName><ForeName>Tsuneyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toda</LastName><ForeName>Tatsushi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaji</LastName><ForeName>Ryuji</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, The University of Tokushima Graduate School, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Haruhisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. haruhisa@cira.kyoto-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iPSC-Based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan. haruhisa@cira.kyoto-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical-Risk Avoidance Based On iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan. haruhisa@cira.kyoto-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497390">SREBF2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497391">Srebf2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051782">Sterol Regulatory Element Binding Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013261">Sterols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051782" MajorTopicYN="Y">Sterol Regulatory Element Binding Protein 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013261" MajorTopicYN="N">Sterols</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35568729</ArticleId><ArticleId IdType="pmc">PMC9107471</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-12133-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-12133-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004;27:723&#x2013;749. doi: 10.1146/annurev.neuro.27.070203.144244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144244</ArticleId><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo V, et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology. 2013;80:829&#x2013;838. doi: 10.1212/WNL.0b013e3182840689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182840689</ArticleId><ArticleId IdType="pmc">PMC3598455</ArticleId><ArticleId IdType="pubmed">23390184</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, et al. Effect of presymptomatic body mass index and consumption of fat and alcohol on amyotrophic lateral sclerosis. JAMA Neurol. 2015;72:1155&#x2013;1162. doi: 10.1001/jamaneurol.2015.1584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.1584</ArticleId><ArticleId IdType="pubmed">26280944</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Khan R, Polymenidou M, Schulz PE. Disease-modifying effects of metabolic perturbations in ALS/FTLD. Mol. Neurodegener. 2018;13:63. doi: 10.1186/s13024-018-0294-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0294-0</ArticleId><ArticleId IdType="pmc">PMC6278047</ArticleId><ArticleId IdType="pubmed">30509290</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Ann. Neurol. 2017;81:718&#x2013;728. doi: 10.1002/ana.24936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, et al. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J. Neurol. 2011;258:613&#x2013;617. doi: 10.1007/s00415-010-5805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Tang L, Huang T, Fan D. Life course adiposity and amyotrophic lateral sclerosis: A Mendelian randomization study. Ann. Neurol. 2020;87:434&#x2013;441. doi: 10.1002/ana.25671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25671</ArticleId><ArticleId IdType="pubmed">31916305</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergani A, et al. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J. Lipid Res. 2007;48:1571&#x2013;1580. doi: 10.1194/jlr.M700017-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M700017-JLR200</ArticleId><ArticleId IdType="pmc">PMC1974855</ArticleId><ArticleId IdType="pubmed">17438338</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SM, et al. Amyotrophic lateral sclerosis is associated with hypolipidemia at the presymptomatic stage in mice. PLoS ONE. 2011;6:e17985. doi: 10.1371/journal.pone.0017985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017985</ArticleId><ArticleId IdType="pmc">PMC3064597</ArticleId><ArticleId IdType="pubmed">21464953</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife. 2019 doi: 10.7554/eLife.45114.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45114</ArticleId><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger SK, Okosun IS, Mitchell CS. Antecedent disease and amyotrophic lateral sclerosis: What is protecting whom? Front. Neurol. 2016;7:47. doi: 10.3389/fneur.2016.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00047</ArticleId><ArticleId IdType="pmc">PMC4810157</ArticleId><ArticleId IdType="pubmed">27065942</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenza M, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 2005;25:9932&#x2013;9939. doi: 10.1523/JNEUROSCI.3355-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3355-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725556</ArticleId><ArticleId IdType="pubmed">16251441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop PJ, et al. Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Sci. Transl. Med. 2022;14:eabj0264. doi: 10.1126/scitranslmed.abj0264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj0264</ArticleId><ArticleId IdType="pubmed">35196023</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012;4:145ra104. doi: 10.1126/scitranslmed.3004052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004052</ArticleId><ArticleId IdType="pubmed">22855461</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumikawa K, et al. TDP-43 stabilises the processing intermediates of mitochondrial transcripts. Sci. Rep. 2017;7:7709. doi: 10.1038/s41598-017-06953-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06953-y</ArticleId><ArticleId IdType="pmc">PMC5550480</ArticleId><ArticleId IdType="pubmed">28794432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957;226:497&#x2013;509. doi: 10.1016/S0021-9258(18)64849-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)64849-5</ArticleId><ArticleId IdType="pubmed">13428781</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzawa N, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology. 2007;46:1392&#x2013;1403. doi: 10.1002/hep.21874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.21874</ArticleId><ArticleId IdType="pubmed">17929294</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331&#x2013;340. doi: 10.1016/S0092-8674(00)80213-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80213-5</ArticleId><ArticleId IdType="pubmed">9150132</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimano H, Sato R. SREBP-regulated lipid metabolism: Convergent physiology-divergent pathophysiology. Nat. Rev. Endocrinol. 2017;13:710&#x2013;730. doi: 10.1038/nrendo.2017.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2017.91</ArticleId><ArticleId IdType="pubmed">28849786</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59&#x2013;72. doi: 10.1016/j.brainres.2013.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.10.013</ArticleId><ArticleId IdType="pubmed">24141148</ArticleId></ArticleIdList></Reference><Reference><Citation>Saher G, Stumpf SK. Cholesterol in myelin biogenesis and hypomyelinating disorders. Biochim. Biophys. Acta. 1851;1083&#x2013;1094:2015. doi: 10.1016/j.bbalip.2015.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2015.02.010</ArticleId><ArticleId IdType="pubmed">25724171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho WY, et al. TDP-43 mediates SREBF2-regulated gene expression required for oligodendrocyte myelination. J. Cell Biol. 2021 doi: 10.1083/jcb.201910213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201910213</ArticleId><ArticleId IdType="pmc">PMC8348376</ArticleId><ArticleId IdType="pubmed">34347016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 2012;15:1488&#x2013;1497. doi: 10.1038/nn.3230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3230</ArticleId><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J. Exp. Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, et al. Neutral lipid cacostasis contributes to disease pathogenesis in amyotrophic lateral sclerosis. J. Neurosci. 2020;40:9137&#x2013;9147. doi: 10.1523/JNEUROSCI.1388-20.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1388-20.2020</ArticleId><ArticleId IdType="pmc">PMC7673008</ArticleId><ArticleId IdType="pubmed">33051352</ArticleId></ArticleIdList></Reference><Reference><Citation>Canet-Pons J, et al. Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression. Neurobiol. Dis. 2021;152:105289. doi: 10.1016/j.nbd.2021.105289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105289</ArticleId><ArticleId IdType="pubmed">33577922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed A, Saavedra L, Di Pardo A, Sipione S, PossedeChaves E. Beta-amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage. J. Neurosci. 2012;32:6490&#x2013;6500. doi: 10.1523/JNEUROSCI.0630-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0630-12.2012</ArticleId><ArticleId IdType="pmc">PMC6621131</ArticleId><ArticleId IdType="pubmed">22573671</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease. Nat. Rev. Neurol. 2011;7:561&#x2013;572. doi: 10.1038/nrneurol.2011.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.132</ArticleId><ArticleId IdType="pubmed">21894212</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs Investig. Drugs J. 2010;13:568&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058503</ArticleId><ArticleId IdType="pubmed">20721828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, et al. A phase II&#x2013;III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 2014;21:529&#x2013;536. doi: 10.1111/ene.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Birolini G, et al. SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington's disease phenotypes. Brain. 2021 doi: 10.1093/brain/awab186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab186</ArticleId><ArticleId IdType="pubmed">33974044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>